As R54 impairs mesenchymal transition CXCL12 induced, the study suggests that R54 may be added to chemotherapy treatment of ovarian cancer to reduce mesenchymal features such as migration/ invasiveness and increase chemotherapy sensitivity. The gene discussed is CXCL12; the disease is ovarian carcinoma.